Last updated: February 5, 2026
What is the Drug Identified by NDC 69452-0255?
NDC 69452-0255 refers to Lecanemab, marketed as Leqembi. It is a monoclonal antibody approved by the FDA in January 2023 for the treatment of Alzheimer’s disease in early stages. The drug targets amyloid beta plaques in the brain.
Market Size and Demand Drivers
Market Size
- Alzheimer’s disease prevalence: An estimated 6.2 million Americans aged 65+ have Alzheimer’s, with projected growth exceeding 12 million by 2050 (Alzheimer’s Association [1]).
- Target population: Early-stage patients eligible for Lecanemab. Approximately 70% of diagnosed individuals are in early stages, equating to roughly 4.3 million potential U.S. patients.
- Global market: Worldwide, Alzheimer’s prevalence exceeds 55 million. Modelled global market penetration remains lower given healthcare access disparities.
Demand Drivers
- FDA approval in Jan 2023 spurred initial uptake.
- Healthcare provider adoption depends on clinician familiarity, efficacy perception, and safety profile.
- Pricing and reimbursement policies influence continued use.
Pricing Strategy and Cost Considerations
Competitive Landscape
- Aduhelm (aducanumab): First FDA-approved anti-amyloid therapy, controversial efficacy claims, initial list price of $56,000/year.
- Lecanemab (Leqembi): Demonstrates more consistent amyloid clearance and better safety profile than Aduhelm, per clinical trial data.
- Other pipeline drugs: Donanemab, gantenerumab, and tau-targeted therapies are in trials but face regulatory and clinical development hurdles.
Price Projections and Market Trends
| Year |
Estimated Market Size (USD billions) |
Expected Usage |
Price Range (USD/year) |
Notes |
| 2023 |
0.4 |
10,000+ patients |
$20,000–$30,000 |
Launch year, initial uptake |
| 2024 |
0.8 |
100,000+ patients |
$20,000–$30,000 |
Increased payer coverage, awareness |
| 2025+ |
1.5–2.0 |
200,000+ patients |
$15,000–$25,000 |
Market stabilization, price negotiation |
Predicted decline in per-patient price as biosimilars or generics potentially enter markets and reimbursement pressures increase.
Regulatory and Reimbursement Impact
- Payer coverage (Medicare, private insurers) primarily influences adoption.
- CMS announced coverage with evidence development policy for Alzheimer’s therapies, influencing discounting strategies.
- The availability of financial assistance programs softens initial affordability concerns.
Key Takeaways
- The U.S. Alzheimer’s market exceeds $12 billion, with near-term revenue potential for Lecanemab reaching $0.5–1 billion annually.
- Current list pricing around $26,500/year is positioned to compete with Aduhelm, targeting reimbursement and payer acceptance.
- Adoption curves depend on clinical efficacy, safety, healthcare provider familiarity, and policy shifts.
- Pricing may decrease substantially over the next 3–5 years driven by payer negotiations and competitive pressures physically or through biosimilars.
FAQs
1. How does Lecanemab compare to Aduhelm in efficacy?
Lecanemab has demonstrated better amyloid clearance and a more favorable safety profile in clinical trials, contributing to improved adoption prospects.
2. What are the primary barriers to market penetration?
Coverage and reimbursement uncertainties, clinician adoption hesitancy, and patient affordability limits are key barriers.
3. Can biosimilars influence the price of Lecanemab?
Potential biosimilar entries could significantly lower prices, but regulatory and patent protections may delay this impact.
4. How are payer policies shaping the drug’s market?
Medicare and private insurers’ reimbursement decisions determine prescribing patterns, with policies favoring value-based agreements impacting final pricing.
5. What is the outlook for global sales?
Global adoption is slower; pricing strategies reflect local healthcare system priorities, with emerging markets likely to see delayed but growing uptake.
References
[1] Alzheimer’s Association. (2022). 2022 Alzheimer’s Disease Facts and Figures.
